Abstract 1669P
Background
Studies have shown that patients with cervical intraepithelial neoplasia (CIN) linked to human papillomavirus (HPV) experience shame and/or guilt due to the association of HPV with sexual transmission. Likewise, such feelings were also reported by cervical cancer (CC) patients. Understanding the similarities or differences in the relationship between guilt, shame, and quality of life (QoL) among these two groups might shed light on effective psychosocial interventions.
Methods
The study employed a cross-sectional design. Patients diagnosed with CIN (n=105, 11.42% CIN 1, 15.23% CIN 2, 58.09% CIN 3, 8.57% unknown) and CC (n=87, 16.09% stage 1, 17.24% stage 2, 36.78% stage 3, 8.04% stage 4, 8.04% were diagnosed with CIN that later progressed, 8.04% were uncertain about their stage at diagnosis, 5.74% unknown) who were recruited through social networks specific to CIN and CC patients completed self-report questionnaires assessing demographic information, medical history, QoL, and feelings of shame and guilt.
Results
The preliminary results revealed a significant negative association between both guilt and shame and QoL in both groups. However, no significant difference in QoL was found between CIN and CC patients (57.12, 52.26 respectively, p=0.1). Additionally, a significant higher level of guilt was reported by CIN patients (13.42) compared to CC patients (10.26) (d=0.58, p=0.0001). There was no significant difference in shame reported by CIN patients compared to CC patients (12.8, 11.37 respectively, p=0.07).
Conclusions
The findings underscore the detrimental role of shame and guilt in the perception of QoL of patients with CIN and CC. Addressing these negative feelings through targeted interventions may be crucial for improving overall well-being in these populations and enhancing their coping mechanisms. Further research involving a larger sample size may provide deeper insights into the differences and similarities between CIN and CC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
HaBait Shel Bar - Israel Women's Cancer Association (RA) in collaboration with Ariel University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1687P - Perceptions of genetic testing and lived experiences in women with locally advanced or metastatic ovarian cancer: A focus on BRCAm and BRCAwt patients
Presenter: María Jesús Rubio Pérez
Session: Poster session 11
1688P - Psychosocial distress and spirituality among elderly patients with cancer in Nigeria
Presenter: Zainab Ogunjimi
Session: Poster session 11
1689TiP - The social stigma of smokers and patients with lung cancer: Detection of phoenomenon and testing of EMDR (eye movement desensitization and reprocessing) intervention
Presenter: Domenico Galetta
Session: Poster session 11
1692P - A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002/ BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced renal cell carcinoma
Presenter: Xinan Sheng
Session: Poster session 11
1693P - CaboPoint: Final results from a phase II study of cabozantinib after checkpoint inhibitor (CPI) combinations in patients with advanced renal cell carcinoma (aRCC)
Presenter: Laurence Albiges
Session: Poster session 11
1695P - Phase I LITESPARK-018: Dose escalation study of belzutifan in advanced pretreated clear cell renal cell carcinoma (ccRCC)
Presenter: Ulka Vaishampayan
Session: Poster session 11
1696P - A phase I/ II trial of pazopanib (Paz) alternating (alt) with bevacizumab (Bev) in treatment-naïve metastatic clear cell renal cell carcinoma (mccRCC) patients (pts): Phase II results
Presenter: Saby George
Session: Poster session 11
1697P - Phase II randomized double-blind trial of axitinib (Axi) +/- PF 04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC): Final analysis
Presenter: Sarmad Sadeghi
Session: Poster session 11
1698P - Avelumab + axitinib (Ave + Axi) vs sunitinib (Sun) in advanced renal cell carcinoma (aRCC): Final analysis of patient (pt)-reported outcomes (PROs) and quality-adjusted time without symptoms or toxicity (Q-TWiST)
Presenter: Balaji Venugopal
Session: Poster session 11